Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 25 of the 49 sources its claims cite were checked for support.

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial

Open access
Mamas, Mamas A, Bays, Harold, Li, Runjia, Upadhyay, Navneet, Irani, Tanya, Senyucel, Cagri, Dunn, Julia P, Liu-Seifert, Hong · 2025 · European Heart Journal Open

Abstract

Abstract Aims Approximately two-thirds of obesity-related mortality is attributable to cardiovascular disease (CVD). The aim of this analysis is to examine predicted CVD risk reduction following weight loss in persons with obesity for primary prevention between tirzepatide and semaglutide, and projected CVD events that could be potentially prevented in the USA. Methods and results SURMOUNT-5 was a Phase 3b, open-label, randomized trial conducted in participants with obesity and without Type-2 diabetes, comparing tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg) and administered via weekly subcutaneous injection. Predicted 10-year CVD risks were compared between treatments at baseline and up to 72 weeks post-treatment among participants without prior CVD. The impact of cardiovascular risk reduction was estimated as the projected preventable CVD events over 10 years for tirzepatide and semaglutide in the USA. The average predicted 10-year CVD risk score before treatment was 9.3%. Treatment with tirzepatide was associated with significantly greater reduction in predicted 10-year CVD risk compared with semaglutide (absolute reduction from baseline of 2.4% and 1.4%, respectively, P < 0.001). Translating risk reduction to the US population who met treatment eligibility criteria and without prior CVD (∼85 million), an estimated 2 million CVD events could be potentially prevented over 10 years after 72 weeks of tirzepatide treatment, vs. 1.15 million with semaglutide. Conclusion In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide. This post hoc analysis suggests tirzepatide treatment may provide greater benefit in primary prevention of CVD than semaglutide in people with obesity and overweight. Registration ClinicalTrials.gov: NCT05822830

Overview

CoChat Summary

## TL;DR

In this post hoc analysis of SURMOUNT-5, tirzepatide was associated with a larger predicted 10-year CVD risk reduction than semaglutide in adults with obesity or overweight without diabetes or prior CVD. The modeled benefit translated to an estimated 2.0 million preventable CVD events over 10 years with tirzepatide vs 1.15 million with semaglutide in an eligible U.S. population.

## Key findings

  • Among 576 participants without pre-existing CVD who completed 72 weeks, mean baseline predicted 10-year CVD risk was 9.3%.
  • At 72 weeks, the absolute reduction in predicted 10-year CVD risk was 2.36% with tirzepatide vs 1.35% with semaglutide, with P < 0.001.
  • Relative reduction from baseline was 23.72% with tirzepatide vs 13.56% with semaglutide (P < 0.001); the marginal HR was estimated as 0.87.
  • In the U.S. treatment-eligible population without prior CVD (about 85 million), the model projected 2.0 million CVD events potentially prevented over 10 years with tirzepatide vs 1.15 million with semaglutide.

## Methods

  • Post hoc analysis of the phase 3b, multicentre, open-label, randomized, active-controlled SURMOUNT-5 trial comparing weekly subcutaneous tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg) for 72 weeks.
  • Analysis used patient-level data from participants without baseline CVD events; 576 participants who completed treatment were included in the per-protocol, complete-case analysis.
  • Predicted 10-year CVD risk was calculated using Framingham-based BMI-specific sex-specific equations, and treatment differences were tested with ANCOVA adjusting for baseline risk score, prediabetes status, BMI group, sex, and age; subgroup analyses examined sex, race, and BMI group.
  • U.S. population impact was projected using NHANES 2021–23 sample-weighted estimates of treatment-eligible adults without diabetes or prior CVD.

## Limitations

  • The paper states that the Framingham risk equations were developed in a predominantly White population; although sensitivity analyses with the AHA PREVENT formula were directionally consistent, the authors note that more racially diverse data are needed.
  • The “prevented events” estimate was a scenario-based projection rather than an observed outcome.
  • The semaglutide dose mix in SURMOUNT-5 included both 1.7 mg and 2.4 mg, and the authors note this may limit generalizability to settings where only 2.4 mg is an approved maintenance dose.
  • Smoking status was only collected at baseline, so the study may underestimate overall CVD risk reduction if some participants quit smoking during follow-up.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ehjopen/oeaf117

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Percent change from baseline in cardiovascular risk (%), in tirzepatide vs. semaglutide. Data are least-square mean for per cent (%) change from baseline. Error bars indicate standard error. MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.
Figure 1 Percent change from baseline in cardiovascular risk (%), in tirzepatide vs. semaglutide. Data are least-square mean for per cent (%) change from baseline. Error bars indicate standard error. MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.CC BY · PubMed Central
Figure 2 Percent change from baseline (PCFB) in cardiovascular risk, % in tirzepatide vs. semaglutide, by baseline subgroup. BMI, body mass index; MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.
Figure 2 Percent change from baseline (PCFB) in cardiovascular risk, % in tirzepatide vs. semaglutide, by baseline subgroup. BMI, body mass index; MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.CC BY · PubMed Central
Figure 3 Predicted 10-year cardiovascular risk and risk factors in tirzepatide vs. semaglutide from baseline to Week 72. Data are least-square mean for post-baseline 10-year cardiovascular disease risk, and observed mean for baseline 10-year cardiovascular disease risk, body mass index, systolic blood pressure, and the proportion of under treatment for hypertension (%). Error bars indicate standard error. MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.
Figure 3 Predicted 10-year cardiovascular risk and risk factors in tirzepatide vs. semaglutide from baseline to Week 72. Data are least-square mean for post-baseline 10-year cardiovascular disease risk, and observed mean for baseline 10-year cardiovascular disease risk, body mass index, systolic blood pressure, and the proportion of under treatment for hypertension (%). Error bars indicate standard error. MTD, maximum tolerated dose; SEMA, semaglutide; TZP, tirzepatide.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 1 Not valid · 13 Not checked · 30 Own results and interpretations

28 more claims · 4 with their cited sources checked

Create a free account to see all 61 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. CDC, 2021–2023, National Health and Nutrition Examination Survey (NHANES) Data
  2. Waters, 2018, America’s Obesity Crisis. The Health and Economic Costs of Excess Weight

Cited by

See all 24

Metadata

Authors
Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H.
Affiliations
  • Keele University (GB)
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • Eli Lilly (United States) (US)
  • Eli Lilly and Company , 307 E Merrill, Indianapolis, IN 46285 ,
Venue
European Heart Journal Open
Published
2025-08-29
Volume
5
Issue
5
Pages
oeaf117-oeaf117
ISSN
2752-4191 (ISSN-L)
OpenAlex
W4413939100
Cited by
24
References
35
Citations by year
2026: 21 · 2025: 3
FWCI
13.47
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal Open (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tirzepatide, semaglutide, obesity, cardiovascular risk, primary prevention, weight loss, overweight, GLP-1 receptor agonists, GIP/GLP-1 dual agonist

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. https://app.cochat.ai/papers/10.1093/ehjopen/oeaf117
The paper
Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025). Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. European Heart Journal Open. https://doi.org/10.1093/ehjopen/oeaf117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.